Epilepsy Animation

Supernus Pharmaceuticals Initiates Phase III Clinical Trial For Epliga™ In Refractory Partial Onset Epileptic Seizures
Supernus Pharmaceuticals, Inc. announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga™. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Epliga for the adjunctive treatment of refractory partial onset seizures in patients with epilepsy. Epliga is a novel controlled release once-per-day dosage form of oxcarbazepine that is designed to improve compliance and reduce adverse events.

44 Days Left For Epilepsy Articles - Epilepsy Scotland
Journalists have only 44 days left to write about epilepsy if they want to win an award. Epilepsy Scotland will give a £500 prize and trophy for the best story printed about this common condition in the Scottish press between 1 February 2008 and 31 January 2009. Communications Manager Allana Parker explained: "Our award recognises responsible, informative and well written articles on a subject that's rarely talked about. We want epilepsy to make the headlines.

FDA Requires Warnings About Risk Of Suicidal Thoughts And Behavior For Antiepileptic Medications
The U.S. Food and Drug Administration announced it will require the manufacturers of antiepileptic drugs to add to these products' prescribing information, or labeling, a warning that their use increases risk of suicidal thoughts and behaviors (suicidality). The action includes all antiepileptic drugs including those used to treat psychiatric disorders, migraine headaches and other conditions, as well as epilepsy.

ITI Announces New Progress Milestones In Its Development Program For Acute Repetitive Seizure In Epilepsy
ITI, a privately held specialty pharmaceutical company, today announced that the company has achieved several important developments in its epilepsy product program, including - Receipt of Fast Track Designation from the U.S. Food and Drug Administration (FDA) in October 2008 for ITI's product candidate ITI-111 - Completion of an end of Phase 2 meeting with the FDA in November 2008; and - Plans to initiate Phase 3 trials for ITI-111 in the first half of 2009.

Data From Pivotal Study Show Medtronic Deep Brain Stimulation Therapy Reduced Seizure Rate In Patients With Severe Epilepsy
In a clinical trial supported by Medtronic, Inc. (NYSE: MDT), deep brain stimulation (DBS) significantly reduced seizure frequency among patients with medically refractory epilepsy with partial-onset seizures, a form of the neurological condition that does not respond well to antiepileptic drugs.

Convergence Of Technology Shows Potential For Restoring Brain Function, Targeted Cell Therapy And New Imaging Techniques
Epileptologists are constantly searching for non-invasive or minimally invasive ways to uncover and describe the brain down to its most fundamental cellular and molecular detail and function. Their goal is to achieve the ability to locate and treat the specific cells, neurons or network that start the train of events that produce seizures. Another is to restore cognitive function after possible injury from continuous seizures.

For Patients With Partial-Onset Seizures - New Keppra XR Data Highlight Its Role
Studies presented at American Epilepsy Society Annual Meeting UCB has announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR™ (levetiracetam) extended-release tablets comparing tolerability vs. levetiracetam immediate release and reporting on additional dosing schedules. The data were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society in Seattle.

Despite FDA Suicide Warning Epilepsy Experts Urge Patients And Caregivers To Continue Drug Therapy
Medical specialists at the nation's largest professional meeting on epilepsy discussed multiple questions and concerns they have about data presented by the FDA in support of its recent suicide alert on anticonvulsant drugs (AEDs) and the potential effect of the federal agency's analyses on clinical practice and the way AED drug trials are to be conducted in the future.

New Keppra XR(TM) Data Highlight Its Role For Patients With Partial-Onset Seizures
UCB announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets comparing tolerability versus levetiracetam immediate release (IR) and reporting on additional dosing schedules. The data were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society (AES) in Seattle. Keppra XR was approved by the U.S.

Minimum Standards Of Care For Epilepsy Proposed By Experts
Leading epilepsy specialists met at the American Epilepsy Society annual meeting in Seattle to unveil a recently published consensus report that proposes minimum standards of care for diagnosing, treating and monitoring epilepsy.

Epilepsy Drug Shows Potential For Alzheimer's Treatment
A drug commonly used to treat epilepsy could help clear the plaques in the brain associated with Alzheimer's disease, according to researchers at the University of Leeds. The plaques are known to lead to the progressive death of nerve cells in the brain linked to many forms of dementia.

Anti-Seizure Medication Can Safely Be Withdrawn From Children With Epilepsy
A new Mayo Clinic study found that it is generally safe to withdraw anti-seizure medications in children with epilepsy who have achieved seizure-freedom while on the medication. Researchers found that these children were not at high risk of subsequently developing intractable epilepsy. The study was presented at the American Epilepsy Society's annual meeting in Seattle. Epilepsy is a disorder characterized by the occurrence of two or more seizures.

Efficacy Of New Seizure Screening Algorithm - Positive Data On Novel Neurodiagnostic Technology
A study by researchers at the Johns Hopkins University School of Medicine reports that a new seizure diagnostics algorithm developed by Baltimore-based Infinite Biomedical Technologies (IBT) accurately screens patients with nonconvulsive seizures.

Multiple Vimpat(R) (lacosamide) Studies Presented At American Epilepsy Society Annual Meeting
UCB announced new findings from analyses of pooled Vimpat(R) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of treatment and across doses in a challenging patient population, when administered as adjunctive therapy. The analyses also showed that Vimpat(R) provides consistent seizure reduction versus placebo, when added to concomitant AEDs, and that it is generally well-tolerated.

Beyond Seizure Control In The Treatment Of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM)
Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate) Positive data from three phase III studies presented at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM